Cancer treatment is increasingly iterative—progression, resistance, and guideline updates often prompt additional testing. Cryopreservation helps retain the highest-value tissue state for future assays, including those that are hard to run (or less reliable) on FFPE due to fixation-related changes and variable preanalytics. (PMC)
FFPE RNA quality can be highly variable; fragmentation and chemical modifications are common and can limit some transcriptomic workflows. Fresh-frozen/viable preservation can reduce these constraints and support modern “omics” strategies as they become clinically available. (PMC)
Single-cell and multi-omics approaches depend on preserving biologic complexity. Multiple studies show that viable cryopreservation can retain cellular diversity and produce high-quality single-cell data suitable for deep profiling—supporting biomarker discovery and trial matching. (PMC)
Trials increasingly specify biomarker requirements (and sometimes fresh/viable tissue preferences). Preserving viable tissue can reduce re-biopsy pressure and accelerate eligibility workflows when trial opportunities emerge. (Trial requirements vary by protocol; SpeciCare supports protocol-based collection planning.) (PMC)
Cancer treatment is increasingly iterative—progression, resistance, and guideline updates often prompt additional testing. Cryopreservation helps retain the highest-value tissue state for future assays, including those that are hard to run (or less reliable) on FFPE due to fixation-related changes and variable preanalytics. (PMC)
FFPE RNA quality can be highly variable; fragmentation and chemical modifications are common and can limit some transcriptomic workflows. Fresh-frozen/viable preservation can reduce these constraints and support modern “omics” strategies as they become clinically available. (PMC)
Single-cell and multi-omics approaches depend on preserving biologic complexity. Multiple studies show that viable cryopreservation can retain cellular diversity and produce high-quality single-cell data suitable for deep profiling—supporting biomarker discovery and trial matching. (PMC)
Clinicians know the downstream reality: cold ischemia time, fixation duration, and processing variability can materially affect molecular readouts. A cryopreservation pathway can be implemented alongside standard FFPE, with controlled handling steps designed to protect downstream analytic performance. (ASCO Publications)
Trials increasingly specify biomarker requirements (and sometimes fresh/viable tissue preferences). Preserving viable tissue can reduce re-biopsy pressure and accelerate eligibility workflows when trial opportunities emerge. (Trial requirements vary by protocol; SpeciCare supports protocol-based collection planning.) (PMC)
Cryopreservation is additive, not disruptive. Most cases maintain standard diagnostic FFPE workflows; cryopreservation is an adjunct pathway designed for future testing optionality and trial enablement.
Common triggers:
SpeciCare provides a kit and a collection plan that clarifies:
Preanalytics remain critical. Professional guidance emphasizes minimizing cold ischemia and controlling processing variables for biomarker fidelity. SpeciCare’s workflow is built to reduce variability while coexisting with standard fixation requirements. (College of American Pathologists)
Specimen is placed into the SpeciCare-prescribed containment/medium and prepared for cold-chain transport per kit instructions.
Courier pickup and tracking. (If you have a preferred courier or institutional shipping SOP, SpeciCare can align to it.)
Tissue is stored for future use in:
Need help right now? Call SpeciCare. We can coordinate directly with pathology, surgery centers, and hospital receiving.
